Skip to main content
TipRanks
Go Ultimate75% OFF

Novartis India Limited (NOVARTIND) AI Stock Analysis

1 Followers
IN:NOVARTIND

Novartis India Limited

(NSE:NOVARTIND)

Select Model
Rating:68Neutral
Price Target:INR 1,491.00â–²(8.97% Upside)
Action:downgraded
Date:11/12/26

The score is primarily driven by the strong financial position from an exceptional balance sheet and healthy cash flows. Mixed technical indicators and a negative P/E ratio are the main limiting factors.

Positive Factors
Conservative Balance SheetExtremely low leverage reduces financial risk and interest burden, giving Novartis India greater resilience if operating conditions weaken. The strong equity base also preserves flexibility to support commercialization, maintain distributions, or pursue growth without depending heavily on external borrowing.
Negative Factors
Uneven Revenue GrowthThe irregular revenue path shows that growth has not been consistently dependable, despite the sharper improvement in 2026. Uneven top-line performance can make future earnings planning less predictable and may limit the visibility of sustained expansion across the company’s marketed portfolio.

Novartis India Limited (NOVARTIND) vs. iShares MSCI India ETF (INDA)

-50%0%50%100%150%200%IN:NOVARTIND+100.60%INDA-2.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 34.07B
Dividend Yield
1.54%
Average Volume (3M)
12.01K
Price to Earnings (P/E)
-862.5
Beta (1Y)
-0.15
Revenue Growth
-5.20%
EPS Growth
-103.74%
Country
India
Employees
59
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Novartis India Limited Business Overview & Revenue Model

Company Description

Evonile Pharma Limited, an affiliate of Novartis AG, operates as a healthcare enterprise primarily within India. The company's diverse portfolio encompasses a range of therapeutic solutions. These include bone and pain management treatments sold unde...

How the Company Makes Money

Novartis India Limited primarily makes money by commercializing pharmaceutical products in India. Its core revenue stream is the sale of branded prescription medicines to customers such as hospitals, pharmacies, distributors, and other healthcare cha...

Novartis India Limited Financial Statement Overview

Summary

Strong balance sheet with near-zero debt and robust cash flows support stability, though revenue declines have limited income statement performance.

Income Statement

64Positive

Balance Sheet

94Very Positive

Cash Flow

79Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue3.36B3.54B3.98B3.35B3.79B3.88B
Gross Profit1.04B1.33B1.53B1.32B1.77B2.06B
EBITDA548.20M941.00M1.33B652.60M1.23B106.60M
Net Income-39.90M931.80M1.01B851.90M1.03B-37.20M
Balance Sheet
Total Assets22.78B9.78B9.48B9.25B9.83B9.58B
Cash, Cash Equivalents and Short-Term Investments3.03B6.68B6.37B5.85B5.70B5.16B
Total Debt7.96B32.10M50.60M69.70M215.10M240.10M
Total Liabilities15.06B1.60B1.63B1.80B2.07B2.66B
Stockholders Equity7.72B8.18B7.85B7.45B7.76B6.92B
Cash Flow
Free Cash Flow0843.60M745.70M1.48B444.90M381.70M
Operating Cash Flow0847.00M745.70M1.13B448.00M386.70M
Investing Cash Flow0-203.40M-33.10M331.30M-1.53B870.40M
Financing Cash Flow0-639.30M-641.50M-1.21B-304.80M-356.30M

Novartis India Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price1368.25

Price Trends

50DMA1607.02Negative
100DMA1461.73Negative
200DMA1185.13Positive

Market Momentum

MACD-39.88Positive
RSI35.89Neutral
STOCH9.41Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NOVARTIND, the sentiment is Negative. The current price of 1368.25 is below the 20-day moving average (MA) of 1487.15, below the 50-day MA of 1607.02, and above the 200-day MA of 1185.13, indicating a neutral trend. The MACD of -39.88 indicates Positive momentum. The RSI at 35.89 is Neutral, neither overbought nor oversold. The STOCH value of 9.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NOVARTIND.

Novartis India Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:NOVARTIND against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:CIPLAIN:CIPLA73OutperformINR 1.14T39.45―2.05%-0.74%-46.77%
IN:NOVARTINDIN:NOVARTIND68NeutralINR 47.86B-862.50―1.54%-5.20%-103.74%
IN:LUPININ:LUPIN67NeutralINR 919.16B17.68―0.90%24.22%20.24%
IN:GLENMARKIN:GLENMARK66NeutralINR 747.33B51.49―0.19%-0.11%43.72%
IN:DRREDDYIN:DRREDDY62NeutralINR 1.16T41.38―0.58%-3.60%-52.23%
IN:ASTRAZENIN:ASTRAZEN59NeutralINR 153.96B86.76―0.58%29.70%-10.76%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%IN:NOVARTINDIN:ASTRAZENIN:CIPLAIN:DRREDDYIN:GLENMARKIN:LUPINDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:NOVARTIND and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:NOVARTINDNovartis India Limited1368.25676.4997.79%
IN:ASTRAZENAstraZeneca Pharma India Limited6158.50-2856.75-31.69%
IN:CIPLACipla Ltd1414.95-74.96-5.03%
IN:DRREDDYDr. Reddy's Laboratories Ltd.1390.50173.4714.25%
IN:GLENMARKGlenmark Pharmaceuticals Limited2648.00808.7843.97%
IN:LUPINLupin Limited2010.0025.691.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026